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Inactivation of Ppp1r15a minimises 
weight gain and insulin resistance 
during caloric excess in female mice
Vruti patel1,2, Guillaume Bidault3, Joseph E. Chambers1, Stefania Carobbio3, 
Angharad J. T. everden1, Concepción Garcés1, Lucy E. Dalton1, Fiona M. Gribble3, 
Antonio Vidal-puig3,4 & Stefan J. Marciniak  1,2
Phosphorylation of the translation initiation factor eIF2α within the mediobasal hypothalamus is 
known to suppress food intake, but the role of the eIF2α phosphatases in regulating body weight 
is poorly understood. Mice deficient in active PPP1R15A, a stress-inducible eIF2α phosphatase, 
are healthy and more resistant to endoplasmic reticulum stress than wild type controls. We report 
that when female Ppp1r15a mutant mice are fed a high fat diet they gain less weight than wild type 
littermates owing to reduced food intake. This results in healthy leaner Ppp1r15a mutant animals 
with reduced hepatic steatosis and improved insulin sensitivity, albeit with a possible modest defect 
in insulin secretion. By contrast, no weight differences are observed between wild type and Ppp1r15a 
deficient mice fed a standard diet. We conclude that female mice lacking the C-terminal PP1-binding 
domain of PPP1R15A show reduced dietary intake and preserved glucose tolerance. Our data indicate 
that this results in reduced weight gain and protection from diet-induced obesity.
Mechanisms that govern energy balance have evolved to cope with periods of nutrient scarcity interspersed by 
times of plenty. The intake of excess calories and their storage in adipose tissue is one such mechanism, but it 
can become maladaptive in the face of a high calorie western diet. The resulting epidemic of obesity is impairing 
health in part through increasing the prevalence of type 2 diabetes. By targeting the pathways that promote a 
positive energy balance it may be possible to prevent obesity and reduce its complications.
The endoplasmic reticulum (ER) is an organelle responsible for the biosynthesis of lipids and the folding of 
secretory proteins1. If protein-folding homeostasis (so-called proteostasis) is threatened by the accumulation 
of misfolded proteins inside the ER, the cell experiences ER stress. Pathways that are triggered by ER stress are 
collectively called the unfolded protein response (UPR). Because ER stress is frequently observed in tissues that 
have accumulated excess lipids it is likely that the UPR is also involved in regulating positive energy balance and/
or its associated metabolic complications2.
The UPR comprises three parallel pathways activated by distinct ER stress sensors: IRE1, ATF6 and PERK3. 
PERK plays a critical role in maintaining the health of insulin-secreting beta-cells and so homozygous muta-
tions of the PERK gene in Wolcott-Rallison syndrome manifest as early onset insulin-dependent diabetes4. In 
mice, inactivation of the Perk gene also causes early beta-cell death5. PERK is a member of a kinase family that 
selectively phosphorylates eIF2α on serine 51 to P-eIF2α to trigger the integrated stress response (ISR)6,7. This 
phosphorylation of eIF2α inhibits protein synthesis by preventing translation initiation and thus reduces the 
load of new proteins entering the ER. When eIF2α is phosphorylated, although the synthesis of most proteins is 
inhibited, the mRNA of the transcription factor ATF4 is preferentially translated8. This leads to the induction of 
PPP1R15A (also known as GADD34), which binds protein phosphatase 1 (PP1) and G-actin to dephosphorylate 
P-eIF2α9,10. After a delay of several hours this restores normal levels of translation thus enabling the synthesis of 
targets of the UPR. However, in the context of chronic ER stress the recovery of protein synthesis mediated by 
PPP1R15A contributes to toxicity11,12.
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Figure 1. Inactivation of PPP1R15A reduces ER stress and protects against lipotoxicity in vitro. (a) Immunoblot 
for PPP1R15A, phosphorylated eIF2α (P-eIF2α), total eIF2α (T-eIF2α), ATF4 and CHOP in lysates of wild type 
and Ppp1r15aΔC/ΔC mouse embryonic fibroblasts (MEFs) following treatment with thapsigargin (Tg) 300 nM for 
indicated times. Proteins of the expected sizes are marked with a solid triangle for PPP1R15A or an open triangle 
for PPP1R15A-ΔC. Molecular size markers shown in kDa. (b) Quantification of (a) using ImageJ software. N = 3; 
mean ± SEM; P value calculated by two-way ANOVA. (c–f) Wild type and Ppp1r15aΔC/ΔC MEFs were treated with 
thapsigargin 300 nM for indicated times and RNA was prepared. Ppp1r15a (Exons 1–3), Ppp1r15a (Exons 1–2), 
Atf4, Chop mRNA were quantified relative to beta-actin by qRT-PCR. N = 3; mean ± SEM; P value calculated 
by two-way ANOVA. (g) Immnoblot for puromycin (indicating rate of translation) and tubulin in lysates of 
wild type or Ppp1r15aΔC/ΔC MEFs following treatment with thapsigargin (Tg) 300 nM for indicated times. Ten 
minutes prior to harvesting, puromycin was added to the culture medium at a final concentration of 10 ng/mL. 
Molecular size markers shown in kDa. (h) Immunoreactivity to puromycin within lysates served as a marker of 
protein translation and was quantified using ImageJ software. N = 3; mean ± SEM; P value calculated by two-way 
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We previously showed that inactivation of the Ppp1r15a gene generates phenotypically healthy, fertile mice 
that have increased resilience to ER stress12. Subsequently, loss of PPP1R15A has been shown to protect against 
tissue damage in a model of ER stress-induced disease13. Subtle reduction in the level of P-eIF2α, the substrate 
of PPP1R15A, in mice heterozygous for the eIF2αS51A allele causes obesity, hyperleptinaemia and glucose intol-
erance when the animals are fed a high-fat diet14,15. However, while increased levels of eIF2α phosphorylation 
within the hypothalamus have been shown to reduce food intake16, a recent report suggested that PPP1R15A 
deficient mice, which are impaired in P-eIF2α dephosphorylation, spontaneously become obese17. The specific 
role of PPP1R15A in the regulation of energy balance therefore remains unclear.
We set out to determine the response of PPP1R15A deficient animals to caloric excess using a high-fat diet. 
Contrary to a previous report17, we observed Ppp1r15aΔC/ΔC mice to gain significantly less weight than wild 
type littermates when fed a high-fat diet. Metabolic phenotyping revealed reduced food intake in the absence 
of changes in energy expenditure. Consequently, despite having a likely subtle defect in insulin secretion, 
Ppp1r15aΔC/ΔC mice were resistant to diet induced obesity, remaining leaner and less insulin resistant than their 
wild type littermates fed on a high-fat diet.
Results
Inactivation of PPP1R15A reduces ISR signalling and protects from lipotoxicity in vitro. As 
expected, when mouse embryonic fibroblasts (MEFs) generated from wild type embryos were treated with 
the ER stressor thapsigargin, full length PPP1R15A protein was induced progressively over an 8-hour period 
(Fig. 1a,b). This mirrored the transcriptional induction of Ppp1r15a mRNA (Fig. 1c,d). In Ppp1r15aΔC/ΔC MEFs, 
PPP1R15A-∆C was induced over a similar time course, but to significantly lower levels. A primer pair targeting 
the deleted exon 3, served as a convenient control for genotype (Fig. 1c); while, primers within the remaining 
Ppp1r15aΔC allele enabled us to use endogenous Ppp1r15a mRNA as a readout of the P-eIF2α-ATF4 (ISR) path-
way. Ppp1r15aΔC/ΔC showed no induction of exon 3, but endogenous Ppp1r15aΔC was induced albeit to a much 
lower level than the wild type allele (Fig. 1d). Consistent with this, P-eIF2α peaked in wild type cells at 0.5 hours 
after treatment with thapsigargin, falling back to baseline by 8 hours as PPP1R15A levels rose, while P-eIF2α rose 
monotonically in the Ppp1r15aΔC/ΔC MEFs (Fig. 1a,b). This confirmed that Ppp1r15aΔC/ΔC cells are impaired in 
the dephosphorylation of P-eIF2α during ER stress.
The induction of ATF4 protein was significantly reduced in Ppp1r15aΔC/ΔC MEFs compared with wild type 
controls despite similar levels of Atf4 mRNA (Fig. 1a,b,e). This reflected a more intense inhibition of translation 
in Ppp1r15aΔC/ΔC MEFs (Fig. 1g,h). Consistent with this, cells treated with tunicamycin, which induces ER stress 
more slowly and so inhibits translation more weakly, showed no deficit of ATF4 in the Ppp1r15aΔC/ΔC MEFs 
(Supplementary Fig. 1). The lower levels of ATF4 in thapsigargin-treated Ppp1r15aΔC/ΔC cells reduced induction 
of its target gene Chop (Fig. 1f) and so contributed to the reduced induction of endogenous Ppp1r15aΔC mRNA 
(Fig. 1d).
The reduction in ISR signalling in thapsigargin-treated Ppp1r15aΔC/ΔC cells correlated with reduced tox-
icity of this agent. When wild type and Ppp1r15aΔC/ΔC MEFs were treated for 48 hours with thapsigargin, 
PPP1R15A-deficient cells required significantly higher concentration of drug to reduce viability (Fig. 1i). The satu-
rated free fatty acid palmitate causes cell death in part via the induction of ER stress18–21 and, like thapsigargin, this 
may involve the depletion of ER calcium18,22. We therefore tested whether inactivation of PPP1R15A would protect 
cells from the lipotoxicity of palmitate. Once again, the PPP1R15A-deficient cells required significantly higher 
levels of palmitate to reduce viability (Fig. 1j). Therefore, we concluded that deficiency of PPP1R15A reduced the 
lipotoxic insult induced by palmitate in vitro. As had been observed for thapsigargin, palmitate caused significantly 
higher levels of P-eIF2α and lower levels of CHOP in Ppp1r15aΔC/ΔC MEFs than in controls (Fig. 1k,l).
Inactivation of PPP1R15A reduces weight gain of mice fed a high-fat diet and prevents 
diet-induced hepatic steatosis. Reduced phosphorylation of eIF2α has been shown to enhance weight 
gain of mice fed a high-fat diet14. However, loss of the eIF2α phosphatase PPP1R15A has also been found to cause 
obesity in male mice, but not in females17,23. To examine the effect of PPP1R15A expression in females in greater 
detail, we randomly assigned 6-week old female wild type and Ppp1r15aΔC/ΔC littermates to normal chow or 60% 
high-fat diet. Bodyweights were monitored weekly for the following 10 weeks (Fig. 2a). Strikingly, only when fed 
a 60% high-fat diet, Ppp1r15aΔC/ΔC animals gained less weight than their wild type littermates (Fig. 2a,b). This 
reduced weight did not arise from a runty phenotype, as body length was not significantly different between the 
two genotypes (Fig. 2c).
We then used time domain-NMR to investigate whether the body weight differences reflected differences in 
fat or lean mass. Lean mass was not different between the two genotypes at 6, 17 or 24 weeks (Fig. 2d). However, 
ANOVA with Bonferroni post hoc test. Molecular size markers shown in kDa. (i) MTT assays were carried out to 
measure cell viability of wild type or Ppp1r15aΔC/ΔC MEFs following treatment with the indicated concentrations 
of thapsigargin for 48 hours. N = 3; mean ± SEM; P value calculated by two-way ANOVA with Bonferroni post 
hoc test. (j) MTT assays were carried out to measure cell viability of wild type or Ppp1r15aΔC/ΔC MEFs following 
treatment with the indicated concentrations of palmitate for 48 hours. N = 3; mean ± SEM; P value calculated 
by two-way ANOVA with Bonferroni post hoc test. (k) Immunoblot for PPP1R15A, P-eIF2α, T-eIF2α, ATF4 
and CHOP in lysates of wild type and Ppp1r15aΔC/ΔC mouse embryonic fibroblasts (MEFs) following treatment 
with palmitate 400 µm for indicated times. Proteins of the expected sizes are marked with a solid triangle for 
PPP1R15A or an open triangle for PPP1R15A-ΔC. (l) Quantification of (A) using ImageJ software. N = 3; 
mean ± SEM; P value calculated by two-way ANOVA. ***p < 0.001, **p < 0.01, *p < 0.05.
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although accretion of fat mass rose progressively in both groups, the increase was significantly attenuated in the 
Ppp1r15aΔC/ΔC animals at 17 and 24 weeks (Fig. 2e). Organ weight measurements at 24 weeks were not different 
between genotypes – only gonadal white adipose tissue mass was significantly reduced in the Ppp1r15aΔC/ΔC 
animals compared with the wild type group (Fig. 2f,g). The 1 g difference in the weight of subcutaneous white 
fat (Fig. 2f) could not account entirely for the difference in mean weight between the two groups (8 g at 17 weeks 
of age; Fig. 2a,b). Since the time domain-NMR showed this difference arose from fat rather than lean mass, it is 
likely that non-measured sources of fat, e.g. within the periteum, also contributed to the reduced corpulence of 
the Ppp1r15aΔC/ΔC animals compared with their sisters.
These findings confirmed that differences in bodyweight between the genotypes resulted from reduced fat 
expansion in the Ppp1r15aΔC/ΔC mice rather than differences in linear growth per se.
In accordance with a healthy lean phenotype observed in Ppp1r15aΔC/ΔC mice, histological analysis and 
neutral lipid staining revealed reduced hepatic steatosis in Ppp1r15aΔC/ΔC mice fed a high-fat diet compared to 
the wild type controls (Fig. 3a). It has previously been described that over-expression of PPP1R15A attenuates 
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Figure 2. Inactivation of PPP1R15A reduces weight gain following a 60% high-fat diet in vivo: (a) At 6 weeks 
of age, wild type and Ppp1r15aΔC/ΔC mice were fed either standard chow diet or 60% high-fat diet and their 
bodyweights measured. P value calculated by two-way ANOVA. (b) Representative images of wild type and 
Ppp1r15aΔC/ΔC mice fed a 60% high-fat diet for 18 weeks. (c) Length of each mouse was measured at time of 
harvest. (d,e) Using time domain nuclear magnetic resonance (TD-NMR), the (d) lean mass, and (e) fat mass 
of the mice were measured prior to high-fat feeding (6-weeks), during high-fat feeding (17-weeks) and at 
the end of the study (24-weeks). (f) The wet weights of each adipose tissue were measured at harvest. Brown 
adipose tissue (BAT); gonadal white adipose tissue (gWAT) and subcutaneous white adipose tissue (scWAT). 
(g) The organs of each mouse were also harvested at the end of the study and wet weights measured. N = 7; 
mean plotted ± SEM; unpaired Student’s unpaired t-test used for statistical analysis. ***p < 0.001, **p < 0.01, 
*p < 0.05.
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hepatic lipid biogenesis by preventing the accumulation of P-eIF2α and thus skewing lipogenic transcriptional 
programmes24. However, our analysis of the expression of genes involved in hepatic lipid metabolism in wild type 
and Ppp1r15aΔC/ΔC mice fed on high-fat diet for 12 weeks revealed no differences between the two genotypes in 
Figure 3. Ppp1r15aΔC/ΔC mice show reduced hepatic steatosis following high-fat feeding but no changes in 
expression of hepatic lipogenic enzymes. (a) To determine hepatic liver content, liver dissected from wild type 
and Ppp1r15aΔC/ΔC mice was frozen in liquid nitrogen. Fifteen-micrometre sections of liver were cut using a 
cryostat and stained using Oil Red O lipid stain and counterstained with haematoxylin (OROH). Representative 
images are shown. Scale bar: 50 μm. (b–g) RNA was prepared from liver taken from wild type (WT) and 
Ppp1r15aΔC/ΔC (∆C/∆C) mice fed a high-fat diet for 12 weeks. Pparg, Scd1, Pck1, Fasn, Acaca, and Cebpb 
mRNA were quantified relative to actb by qRT-PCR. N = 4–9; mean plotted ± SEM; none of the mRNA levels 
were significantly different by unpaired Student’s unpaired t-test.
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Figure 4. Metabolic phenotyping of wild type and Ppp1r15aΔC/ΔC mice indicate reduced food intake following 
high-fat feeding. (a) Mice were single housed at 17-weeks old and food intake was measured three times a 
week, for 2-weeks. Following food intake measurements, indirect calorimetry was carried out over 48 hours. 
Food intake, fat mass gain and energy expenditure were calculated. RNA was prepared from brown adipose 
tissue taken from wild type (WT) and Ppp1r15aΔC/ΔC (∆C/∆C) mice fed a high-fat diet for 18 weeks. P value 
calculated by unpaired Student’s t-test. (b–d) Pgc1a, Elovl3 and Dio2 mRNA were quantified relative to the 
geometrical mean of actb, 36b4, 18S and B2M by qRT-PCR referred to as BestKeeper (BK). RNA was prepared 
from subcutaneous brown adipose tissue taken from wild type and Ppp1r15aΔC/ΔC mice fed a high-fat diet for 18 
weeks. (e–g) Pgc1a, Elovl3 and Dio2 mRNA were quantified relative to the geometrical mean of actb, 36b4, 18S 
and B2M by qRT-PCR referred to as BK analysis. RNA was prepared from white adipose tissue taken from wild 
type and Ppp1r15aΔC/ΔC mice fed a high-fat diet for 18 weeks. (h) RNA was prepared from subcutaneous white 
adipose tissue taken from wild type and Ppp1r15aΔC/ΔC mice fed a high-fat diet for 18 weeks and Ucp1 mRNA 
was quantified relative to actb, 36b4, 18S and B2M by qRT-PCR referred to as BK. (i) RNA was prepared from 
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Pparg, Scd1, Pck1, Fasn and Acaca (Fig. 3b–f). Furthermore, expression of Cebpb, a positive regulator of hepatic 
Pparɣ25,26, was similar in both genotypes (Fig. 3g). These results suggest that the reduced hepatic steatosis of 
Ppp1r15aΔC/ΔC mice was related to a healthy phenotype resulting from decreased exogenous input and reduced 
adiposity.
Ppp1r15a mutant animals consume less high-fat food without altering energy expenditure. 
We then investigated the factors contributing to the resistance of Ppp1r15aΔC/ΔC mice to high-fat diet-induced 
obesity. As shown in Fig. 2, by 12 weeks on a high-fat diet the bodyweights of wild type and Ppp1r15aΔC/ΔC 
mice were diverging. Therefore at 12 weeks, food intake of singly-housed mice was measured over a 2-week 
period. This was followed by metabolic rate measurements using indirect calorimetry for a further 48 hours. Food 
intake, fat mass gained and energy expenditure were calculated as total energy per day for each mouse (Fig. 4a). 
Ppp1r15aΔC/ΔC mice showed a significant 16% reduction in food intake compared with wild type controls indi-
cating that inactivation of PPP1R15A selectively decreased the consumption of the high-fat diet (Fig. 4a). In the 
absence of a conditional allele of Ppp1r15a it remains to be determined if these differences stem from a function 
of PPP1R15A in central or peripheral tissues. With respect to energy dissipation, we observed no significant dif-
ferences in energy expenditure between the two genotypes, nor differences in the expression of the thermoregu-
latory genes, Pgc1α, Elovl3 and Dio2, either in brown (Fig. 4b–d) or white adipose tissue (Fig. 4e–g). In the brown 
adipose tissue, we observed a small increase in Ucp1 mRNA and protein (Fig. 4h–k), which was not associated 
with a decreased respiratory exchange ratio (RER) or an increase in energy expenditure, indicating no preferen-
tial oxidation of fatty acids in the Ppp1r15aΔC/ΔC mice (Fig. 4l). These results argue against PPP1R15A having a 
major impact on the thermogenic activity of brown and subcutaneous white adipose tissue. Additionally, physical 
activity rates were indistinguishable between the genotypes (Fig. 4m). Thus, the main contributor to resistance to 
weight gain was decreased food consumption.
Glucose tolerance and insulin tolerance testing in wild type and Ppp1r15aΔC/ΔC mice. Reduced 
body weight is not always a sign of health as it is observed in animals with primary adipose tissue dysfunction or 
lipodystrophy. Thus it was important to determine if the differences in weight gain were associated with improved 
glucose homeostasis in Ppp1r15aΔC/ΔC mice. The glucose tolerance test of mice fed a high-fat diet unexpect-
edly revealed a hyperglycaemic response in Ppp1r15aΔC/ΔC animals at 20 and 30 minutes following the intra-
peritoneal injection of glucose (Fig. 5a). This suggested that despite being leaner, the Ppp1r15aΔC/ΔC mice were 
slightly less glucose tolerant than their wild type littermates. This counterintuitive effect was relatively modest, as 
the areas under the blood glucose curves were not significantly different between wild type and Ppp1r15aΔC/ΔC  
mice (Fig. 5b). Thus, this could have been the result of insulin resistance or impaired insulin secretion by the 
Ppp1r15aΔC/ΔC mice, although basal and 30 minute insulin levels after glucose administration were not measur-
ably different (Fig. 5c).
To determine their insulin sensitivity, we performed an insulin tolerance test on animals fed a high-fat diet. 
Following the injection of 0.75 U/kg of insulin, blood glucose fell in both groups, although to a significantly 
greater degree in the Ppp1r15aΔC/ΔC mice (Fig. 5e,f). This was seen as both a lower nadir in glucose level and 
a significantly different area under the blood glucose curve. In line with their leaner phenotype, basal levels of 
circulating free fatty acids in high-fat diet-fed Ppp1r15aΔC/ΔC mice were also significantly lower compared to 
wild type controls (Fig. 5d). This indicated that, in keeping with their leanness and reduced free fatty acid levels, 
Ppp1r15aΔC/ΔC animals were more insulin sensitive than their wild type controls. This further suggested a defect 
in insulin secretion since Ppp1r15aΔC/ΔC mice were less glucose tolerant than their wild type littermates.
Of note, although the basal levels of fasting circulating insulin were not significantly different between the 
two genotypes (Fig. 5c), western blot analysis revealed higher levels of insulin within the pancreata of unfasted 
Ppp1r15aΔC/ΔC animals compared with wild type controls (Fig. 5g,h) despite similar levels of insulin mRNA 
(Fig. 5i,j). This also suggested a defect in the secretion of insulin. Loss of PPP1R15A therefore caused opposing 
effects on glucose homeostasis: on the one hand improving insulin sensitivity, most likely via a negative energy 
balance, while also impairing early phase insulin secretion allowing higher peak glucose levels following glucose 
challenge.
Inactivation of PPP1R15A improves glucose tolerance in a model of beta-cell exhaustion. To 
determine if inactivation of PPP1R15A would have a net beneficial or detrimental effect in metabolic disease, 
we set out to model the later stages of type 2 diabetes wherein beta-cell mass falls in the face of sustained insulin 
resistance27. To achieve this, we fed mice a high-fat diet then treated with the beta-cell toxin streptozotocin at a 
dose optimized to cause subtotal beta-cell loss. At age 6 weeks, mice were placed on 60% high-fat diet and at 12 
weeks were injected with 50 mg/kg streptozotocin on five consecutive days to mimic the loss of beta-cell mass 
seen in advanced type 2 diabetes27. As expected, streptozotocin injection induced weight loss (Fig. 6a) and a 
brown adipose tissue taken from wild type and Ppp1r15aΔC/ΔC mice fed a high-fat diet for 18 weeks and Ucp1 
mRNA expression was quantified relative to actb, 36b4, 18S and B2M by qRT-PCR and BK analysis.  
(j) Immunoblot for UCP1 and GAPDH of tissue lysates prepared from brown adipose tissue harvested from 
wild type and Ppp1r15aΔC/ΔC mice fed a high-fat diet for 18 weeks. Molecular size markers shown in kDa.  
(k) Quantification of (D) using ImageJ software. N = 4–7, mean band intensity plotted ± SEM; unpaired 
Student’s t-test used for statistical analysis. (l,m) Indirect calorimetry was also used to measure the  
(l) respiratory exchange ratio and (m) activity of the mice over 48 hours. N = 7; mean plotted ± SEM; unpaired 
Student’s t-test used for statistical analysis. ***p < 0.001, *p < 0.05.
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Figure 5. Glucose tolerance and insulin tolerance testing of wild type and Ppp1r15aΔC/ΔC mice. (a) At age 22 
weeks (16 weeks on high-fat diet), the mice were fasted for 16 hours, after which mice were intraperitoneally 
injected with 1 g/kg glucose, where the dose used was calculated using the average bodyweight of the full 
cohort of mice. Glucose levels were then measured at 10, 20, 60, 90 and 120 minutes post- injection. P value 
was calculated by two-way ANOVA with post hoc Bonferroni test. (b) Quantification of the glucose tolerance 
test (GTT) carried out using the area under the curve (AUC). (c) Blood samples were collected at 0 minutes 
(basal), prior to glucose injection and at 30 minutes post-injection. Serum was separated out and measured for 
insulin. P value calculated by unpaired Student’s t-test. (d) Free fatty acid levels in the basal serum sample were 
also measured. P value calculated by unpaired Student’s t-test. (e) At age 23 weeks (17 weeks on high-fat diet), 
the mice were fasted for 4 hours, after which mice were intraperitoneally injected with 0.75 U/kg insulin, where 
the dose used was calculated using the average bodyweight of the full cohort of mice. Glucose levels were then 
measured at 10, 20, 60, 90 and 120 minutes post-injection. P value was calculated by two-way ANOVA with post 
hoc Bonferroni test. (f) Quantification of the insulin tolerance test (ITT) was carried out using the AUC. P value 
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progressive increase in fasting glucose in both groups (Fig. 6b). Immunofluorescence staining confirmed that 
islet morphology appeared similar between the genotypes prior to injection with streptozotocin, and both gen-
otypes responded with similar reductions in islet size and falls in circulating insulin (Fig. 6c,d). However, when 
challenged with an intraperitoneal injection of glucose, the Ppp1r15aΔC/ΔC mice were significantly more glucose 
tolerant than wild type animals (Fig. 6e). As expected, both genotypes had higher peak glucose levels compared 
with animals not treated with streptozotocin (compare Figs 5a and 6e), but despite having a partial depleted 
beta-cell mass, Ppp1r15aΔC/ΔC mice no longer showed higher peak glucose levels compared to wild type controls, 
but still displayed an increased glucose clearance (Fig. 6e).
Discussion
We have shown that female mice lacking functional PPP1R15A eat less and gain less weight than wild type ani-
mals when fed a high-fat diet. This leads to reduced fat mass, improved insulin sensitivity, lower levels of circulat-
ing free fatty acids, and less hepatic steatosis in the Ppp1r15a∆C/∆C female mice.
Our observation that female Ppp1r15a∆C/∆C mice remained leaner than controls on a high-fat diet was unex-
pected. The lean phenotype of these animals arises mainly from reduced food intake rather than increased energy 
expenditure, despite the observation that UCP1 expression is mildly increased in the brown adipose tissue (BAT) 
of Ppp1r15a∆C/∆C mice. Importantly, the changes in UCP1 mRNA and protein levels do not necessarily result in 
changes in energy expenditure. For example, the Ucp1 knockout mouse has normal energy expenditure when 
reared at room temperature28. This occurs because energy expenditure in mice is a function of heat dissipation 
to the environment and the requirement to replace lost heat to maintain euthermia; this heat does not have to be 
derived from BAT. Given the normal energy expenditure in our model, the alterations in UCP1 may indicate a 
BAT-specific effect of P-eIF2α on the regulation of UCP1 expression and therefore protein levels that deserves 
further investigation in the future.
Despite reporting this allele more than a decade ago, we had never observed a weight phenotype in this line12. 
However, we had not previously challenged these animals with a high-fat diet. Likewise, the recent report that 
deletion of the Ppp1r15a gene generates male mice that spontaneously become obese and develop fatty liver was 
surprising to us17. In that study, Ppp1r15a deficient mice fed on standard chow (CLEA Rodent Diet CE-2) gained 
more weight than wild type controls, but this became significant only from 6 months of age – much older than is 
typical for our mice to be kept17. By contrast, a subsequent report by the same group failed to show excess obesity 
in female Ppp1r15a deficient mice even by 11–20 months of age23. Indeed, at 11–20 months of age on standard 
chow, 12 of 22 Ppp1r15a deficient females were described as being “lean”, compared with 0 of 37 wild type ani-
mals (Table 1 in reference23). This led us to wonder if female Ppp1r15a deficient mice might display a more subtle 
weight phenotype than had been reported for males. We therefore examined the effects of normal chow versus 
high-fat diets, which revealed reduced weight gain in Ppp1r15a deficient females only when fed a high-fat diet.
A possible explanation for the dichotomous effects of Ppp1r15a loss in female vs male mice might involve the 
effects of oestradiol on hypothalamic lipotoxic ER stress. Reduced oestradiol levels following surgical ovariec-
tomy lead to weight gain through hyperphagia and reduced energy expenditure in female mice29. Restoration of 
body weight following oestradiol replacement has recently been shown to involve a reduction of ER stress-causing 
ceramides within the ventromedial hypothalamus30. Similarly, inhibition of ceramide synthesis reduces hypo-
thalamic ER stress and ameliorates weight gain following ovariectomy. It is tempting therefore to speculate that 
female mice are more susceptible to the weight reducing effects of Ppp1r15a loss because both oestradiol and 
P-eIF2α are predicted to attenuate ER stress within the hypothalamus. A limitation of our present study is the lack 
of head to head comparison of male and female mice. Future studies will be necessary to address any potential 
interaction between PPP1R15A and oestradiol.
Differences between our results and those of Nishio and colleagues17,23 might also relate to the different alleles 
used. PPP1R15A is a large protein of >600 amino acids but only its C-terminal 150 residues are required for its 
phosphatase activity. We recently described how this C-terminal domain is both necessary and sufficient to inter-
act with PP1 and actin to form a functional eIF2α holophosphatase10,31. The different weight phenotypes between 
our Ppp1r15a∆C/∆C mouse versus the complete-deletion mouse may hint to the existence of, as yet, unidentified 
functions of the N-terminal portion of PPP1R15A. To test this, future strain-controlled studies will need to com-
pare these two alleles in head-to-head experiments.
In keeping with the healthy phenotype of our Ppp1r15a∆C/∆C mice, no pathogenic mutations in PPP1R15A 
have yet been reported in humans. Importantly, mutation of PPP1R15A has not been identified in obese or lipo-
dystrophic patients. By contrast, loss-of-function mutations of the constitutively expressed paralogue PPP1R15B 
have been shown to cause developmental defects both in mice32 and humans33. Mice homozygous for an inactive 
mutant allele of Ppp1r15b survive gestation but then die during the neonatal period32. Recently, two siblings with 
early onset diabetes, short stature, microcephaly and learning disability were reported to have a homozygous 
mutation of the PPP1R15B gene33. The mutation affected a conserved arginine in the C-terminal PP1-binding 
domain of PPP1R15B and impaired formation of an active eIF2α holophosphatase when expressed in vitro. 
Although the mechanism by which PPP1R15B inactivation led to beta-cell dysfunction is unclear, it predicts that 
calculated by unpaired Student’s t-test. (g) Immunoblot for insulin and actin in protein lysates prepared from 
whole pancreas extracted from wild type and Ppp1r15aΔC/ΔC mice fed a high-fat diet for 18 weeks.  
(h) Quantification of (g) using ImageJ software. P value calculated by unpaired Student’s t-test. Molecular size 
markers shown in kDa. (i–j) Total RNA was extracted from whole pancreas of wild type and Ppp1r15aΔC/ΔC  
mice fed a high-fat diet for 18 weeks. Ins1 and Ins2 mRNA were quantified relative to actb by qRT-PCR. 
N = 4–7; mean plotted ± SEM; unpaired Student’s unpaired t-test used for statistical analysis.
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Figure 6. Induction of diabetes and measurement of pancreas function following high-fat feeding and 
streptozotocin treatment in wild type and Ppp1r15aΔC/ΔC mice. (a) Six-week old mice were put on a 60% 
high-fat diet for six weeks. At age 12 weeks, mice were injected with 50 mg/kg streptozotocin (STZ) on 5 
consecutive days. Bodyweights of the mice were recorded for 5 weeks post STZ treatment. (b) Non-fasted 
blood glucose of the mice was measured for 5 weeks post STZ treatment. Clinical signs of diabetes assessed 
as mice with blood glucose levels above 20 mM (marked with grey dashed line). (c) Fluorescence microscopy 
images of pancreas sections taken from wild type and Ppp1r15aΔC/ΔC mice fed either a normal chow diet (top 
panel) or 60% high-fat diet and streptozotocin treated (bottom panel). Fixed tissue sections were probed with 
antibodies against glucagon (green) and insulin (red), and counterstained with Hoescht (blue) and imaged by 
confocal microscopy. Scale bar = 50 µm. (d) Circulating insulin levels of STZ-treated mice fed on a high-fat 
diet and shown compared to results from Fig. 5c. (e) Glucose tolerance test (GTT) was carried out on 17-week, 
HFD + STZ treated mice. Mice were fasted overnight, and then injected with 1 g/kg glucose. Blood glucose was 
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non-selective inhibition of P-eIF2α dephosphoryaltion might have negative developmental effects. This high-
lights the need to develop selective PPP1R15A inhibitors.
ER stress links obesity, lipotoxicity and the development of insulin resistance34,35. Professional secretory cells, 
such as insulin secreting beta-cell, are prone to ER stress because they face large swings in the flux of new proteins 
traversing through their ER36. This in turn renders beta-cells especially vulnerable to defects in the UPR signaling 
pathway5. Indeed, mutations that impair the ability of mice or humans to phosphorylate eIF2α during ER stress 
have disproportionately greater effects on the beta-cell compared to other secretory tissues4,5,14,37. Because many 
solid tumours also depend upon eIF2α phosphorylation by PERK to withstand their hypoxic microenviron-
ment38, PERK inhibition has emerged as a potential chemotherapeutic strategy, but in pre-clinical models PERK 
inhibitors rapidly induce beta-cell toxicity, underling the reliance of this cell type on its ability to phosphorylate 
eIF2α39,40. The precise mechanisms linking perturbed eIF2α phosphorylation with beta-cell toxicity are not fully 
understood, but recent observations suggest that proper levels of P-eIF2α are required to maintain appropriate 
levels of the chaperones required for proinsulin proteostasis41.
Phosphorylation of eIF2α has complex effects on energy metabolism. When transgenic mice were generated 
to overexpress the C-terminal PP1 binding domain of PPP1R15A in the liver, they remained leaner than con-
trols when fed a high-fat diet, and showed enhanced glucose tolerance, improved insulin sensitivity and reduced 
hepatic steatosis24. It is noteworthy, however, that phosphorylation of eIF2α had a strikingly biphasic effect on 
hepatic lipid metabolism with lipogenic gene expression being suppressed both at reduced and at elevated levels 
of P-eIF2α24. In addition, loss of hepatic P-eIF2α by overexpression of PPP1R15A has been shown to affect mus-
cle and adipose insulin sensitivity, possibly through altered levels of circulating IGFBP-342. Our observations now 
indicate that P-eIF2α may also affect energy metabolism through effects on dietary intake.
Our observation that Ppp1r15a∆C/∆C mice fed a high-fat diet consume significantly fewer calories compared 
with controls is consistent with a central effect of elevating P-eIF2α. This is in keeping with the known role of 
eIF2α in regulating feeding behaviors. Aversion to diets imbalanced in amino acids has been shown to involve 
GCN2-mediated phosphorylation of eIF2α in the brain, while reduced eIF2α phosphorylation appeared to cor-
relate with increased food intake43. Moreover, pharmacological enhancement of P-eIF2α in the mediobasal hypo-
thalamus with salubrinal has been shown to reduce food intake16. Central ER stress has also been implicated in 
mediating hepatic effects in diet-induced obesity in mice, since overexpression of the chaperone Grp78 in the 
circumventricular subfornical organ reduced hepatic steatosis without affecting weight gain, food intake or adi-
posity44. However, we are unable to exclude an effect of Ppp1r15a∆C/∆C on the secretion of orexigenic or anorexi-
genic hormones that might regulate dietary choice.
Owing to the absence of a conditional knockout allele of Ppp1r15a, we were unable to determine in which 
tissues loss of PPP1R15A is responsible for the food intake phenotype. We examined the expression of ISR targets, 
ATF4 and CHOP, in the hypothalamus by qRT-PCR but failed to detect significant differences (data not shown). 
Whilst this might argue against a central role for PPP1R15A, it is possible that our analysis of total hypothalamic 
mRNA missed differences between individual hypothalamic nuclei. Future studies using conditional deletion 
of Ppp1r15a or more focused analyses of hypothalamic nuclei will therefore be informative. Nevertheless, while 
this represents an important limitation of our study, the inactivation of PPP1R15A throughout the animal gives 
an indication of the effect PPP1R15A inhibition might have in a clinical setting. The complexity of the knockout 
phenotype, with better preservation of insulin sensitivity and yet higher peak glucose levels following glucose 
challenge, led us to question whether PPP1R15A antagonism would be beneficial or detrimental in models of 
diabetes. The direct role of PPP1R15A in insulin secretion in response to glucose remains to be addressed by more 
detailed assessments of in vivo glucose-stimulated insulin secretion. Future studies including frequently sampled 
intravenous glucose tolerance tests45, would help to elucidate the relative importance of PPP1R15A’s effects on 
increased insulin sensitivity and reduced glucose clearance. Our finding that Ppp1r15a mutant mice depleted of 
most beta-cells with streptozotocin have improved glucose tolerance suggests that the beneficial effects on insulin 
sensitivity dominate in the setting of diabetes. This raises the exciting possibility that PPP1R15A inhibition may 
be a potential therapeutic strategy in obesity with insulin resistance or in advanced states of the natural evolution 
towards diet-induced diabetes.
We previously showed that loss of PPP1R15A ameliorated ER stress-induced nephrotoxicity12, which led us 
to speculate that inhibition of eIF2α might protect beta-cell mass in the context of beta-cell exhaustion. Indeed, 
deletion of Chop, a transcription factor responsible for efficient induction of PPP1R15A, was shown to protect 
mice in variety of models of diabetes40,46. However, loss of Ppp1r15a has yet to be tested directly in an animal 
model of diabetes. Instead, efforts have focused on targeting PPP1R15A with small molecules, but these studies 
have been hampered by a lack of potent and selective molecules. Indeed, we recently demonstrated that the puta-
tive PPP1R15A inhibitors guanabenz and sephin1 do not affect PPP1R15A function, highlighting the urgent need 
for effective small molecules47. Salubrinal weakly inhibits dephosphorylation of eIF2α at high concentrations47, 
but its dramatic effects to increase P-eIF2α in cells may reflect additional effects perhaps on one or more of the 
eIF2α kinases. In insulinoma cells, salubrinal was found to enhance the toxicity of palmitate48, but our data indi-
cate that genetic loss of PPP1R15A ameliorates the lipotoxicity of palmitate. This supports a potential therapeutic 
role of PPP1R15A inhibition if more potent and selective small molecules were to be generated.
measured at 0,10, 20, 30, 60, 90 and 120 minutes. N = 7–9; two-way ANOVA and Bonferroni post-hoc test used 
for statistical analysis. (f) Quantification of the GTT carried out using the area under the curve (AUC). P value 
calculated by unpaired Student’s t-test. *p < 0.05.
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In summary, we have observed that mice lacking the C-terminal PP1-binding domain of PPP1R15A are pro-
tected from obesity when fed a high-fat diet. This appears to reflect an increased satiety to diet, resulting in 
reduced weight gain and improved insulin sensitivity.
Experimental Procedures
Mice. The Guide for the care and use of laboratory animals, Eight edition (2011), was followed. The UK Home 
Office approved all animal protocols in this study (PPL 80/2491 & PPL 80/2484). Generation of the Ppp1r15aΔC/ΔC  
mouse (originally named Ppp1r15atm1Dron), has been described11. To minimise effects of genetic background, 
backcrossing was performed (Speed Congenics, Charles River, UK) until 97% C57BL/6 purity. Mice were fed a 
standard chow diet (5.1% fat, SAFE diets U8400G10R) or a semisynthetic high-fat diet (60% fat, Research diets 
D12492i, Research Diets, New Brunswick, NJ). All mice used in this study were female. For treatment with strep-
tozotocin, mice were intraperitoneally injected with 50 mg/kg streptozotocin (Sigma-S0130, Dorset, UK) freshly 
dissolved in sodium citrate pH 4.5.
Metabolic profiling. We performed glucose tolerance tests after a 16-hour fast (5 p.m. to 8 a.m.) and insulin 
tolerance tests after a 4-hour fast (8 a.m. to 12 p.m.). Body composition was measured by time domain NMR 
(Bruker Optics). Daily food intake measurements were carried out on singly-housed mice in surgery bedding 
lined cages. Energy expenditure was measured by indirect-calorimetry in a Metatrace system (Creative Scientific, 
UK) at 21 °C attached to a custom-built oxygen and carbon dioxide monitoring system (Minimox system built 
by P. Murgatroyd). Carbon dioxide concentration in room air and air leaving each cage were measured every 
11 minutes. Activity was assessed by beam breaks set 2.5 cm apart. Activity measurements were taken to be total 
beam breaks, measured every 8 minutes.
Glucose and insulin tolerance tests. Overnight fasted mice were injected intraperitoneally with 1 g/kg 
glucose, calculated using the average bodyweight of the cohort, and blood glucose was measured for 2 hours. For 
the insulin tolerance tests, mice were fasted for 4 hours, basal glucose measured, and then mice were injected 
intraperitoneally with 0.75 U/kg of insulin, calculated using the average bodyweight of the Ppp1r15aΔC/ΔC cohort. 
Measurement of plasma insulin and free fatty acid was carried out using the Meso Scale Discovery (MSD) assays 
at the Core Biochemical Assay Laboratory (CBAL), Cambridge, UK.
Histology. Primary antibodies used were: guinea-pig anti-insulin (ab7842, 1:200; Abcam), rabbit 
anti-glucagon (SC13091, 1:200; SantaCruz, Santa Cruz, CA, USA). Sections were counterstained using Hoechst 
(1:1300, Invitrogen, UK). Stained sections were imaged using either the incubated Zeiss LSM510 META Confocal 
Microscope, Zeiss LSM710 META Confocal Microscope, Zeiss AxioImager Motorised Upright Microscope. 
Images were analysed using Zen software.
Cells and reagents. Wild type and Ppp1r15aΔC/ΔC MEFs were cultured as described12. Prior to experimen-
tation, palmitate was first conjugated to BSA. Palmitic acid (Sigma-P0500, Dorset, UK) was prepared to a con-
centration of 100 mM in 100% (v/v) ethanol and heated at 60 °C. This was added to media supplemented with 5% 
(w/v) fatty-acid free, low endotoxin BSA (Sigma-A8806, Dorset, UK), to prepare a 10X stock and sonicated to 
ensure conjugation and solubilisation.
Immunoblots. Cell lysates were prepared and resolved as described12. Primary antibodies used were: rabbit 
anti-PPP1R15A (10449-1-AP, 1:1000; Proteintech, Manchester, UK), rabbit anti-phospho-eIF2α (3597, 1:1000; 
Cell Signaling), mouse anti-actin (ab3280, 1:1000; Abcam), rabbit anti-ATF4 (C-20, 1:500; SantaCruz, Santa 
Cruz, CA, USA), mouse anti-total eIF2α (AHO0802, 1:1000; Invitrogen, Thermo Fisher Scientific, Waltham, 
MA, USA); guinea pig anti-insulin (ab7842, 1:1000; Abcam), rabbit anti-GAPDH (14C10) (2118, 1:1000; Cell 
Signaling), rabbit anti-UCP1 (ab10983, 1:1000; Abcam), rabbit anti-CHOP (1:1000; kind gift from Professor 
David Ron, Cambridge, UK), rabbit anti-alpha/beta tubulin (2148, 1:1000; Cell Signalling, Hitchin, UK).
RNA extraction and real-time PCR. Total RNA was extracted from mammalian cells using the Qiagen 
RNeasy Mini Kit (Qiagen Ltd., UK), and from animal tissue using TRIzol reagent (15596026, ThermoFisher). 
cDNA was reverse transcribed with M-MLV Reverse Transcriptase (Invitrogen, UK), using an Oligo-(dt)15 
primer (Promega, UK). Real-time PCR was performed using an ABI7900-HT-Fast device (Applied Biosystems, 
Carlsbad, UK). Relative fold-changes of expression were determined using the relative standard curve method or, 
were stated in the legend, BestKeeper analysis49. Primer sequences used can be found in Supplementary Table S1.
Statistics. Data were analysed using unpaired Student’s t-tests or analysis of variance (ANOVA) with 
Bonferroni post hoc correction (Prism, Graphpad, USA).
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